ReviewThe Korean journal of pain2023
Current scenario and future applicability of antivirals against herpes zoster.
Review in The Korean journal of pain, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 17 citations in OpenAlex.
- Integrated Western and Traditional Chinese Medicine Approaches for Herpes Zoster and Post-Herpetic Neuralgia: A Narrative Review.Drug design, development and therapy · 2026Review
- Short-term peripheral nerve stimulation or pulsed radiofrequency in elderly patients with acute herpes zoster ophthalmicus: multi-center retrospective study.The Korean journal of pain · 2026Article
- A Short Review and Update on Epidemiology, Treatment, and Management of Herpes Zoster (Shingles) Infection.Current pharmaceutical design · 2026Review
- Case Report: Herpes zoster-associated abdominal wall bulge with ipsilateral muscle atrophy.Frontiers in medicine · 2026Article
- Review
- Small Molecule Compounds Inhibit Varicella-Zoster Virus Replication by Targeting the Portal Protein-Capsid Interface.Viruses · 2025Article
- Determinants of Hospital Length of Stay in Herpes Zoster Patients: A Four-Year Retrospective Study.Health science reports · 2025Article
- Comparative Case Series of Herpes Zoster in Older Immunocompromised Chinese Adults: Clinical, Immunological, and Treatment Profiles in Four Cases Over 60.Infection and drug resistance · 2025Article
- The Use of Tricyclic Antidepressants for Postherpetic Neuralgia - A Case Series.Health psychology research · 2025Article
- Understanding the Mode of Action of Several Active Ingredients from the Micro-Immunotherapy Medicine 2LZONAJournal of inflammation research · 2025Article
- The Role of Moist Dressings in the Management of Herpes Zoster With Scalp Involvement: A Case Report.Clinical case reports · 2024Article
- Article
- Varicella-zoster virus infection: a review about varicella and herpes zoster.Anais brasileiros de dermatologiaReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Herpes zoster (HZ) is a common disease in the aging population and immunocompromised individuals, with a lifetime risk of 20%-30% that increases with age. HZ is caused by reactivation of the varicella-zoster virus (VZV), which remains latent in the spinal dorsal root ganglia and cranial sensory ganglia after resolution of the primary VZV infection. The main focus of HZ management is rapid recovery from VZV infection as well as the reduction and prevention of zoster-associated pain (ZAP) and postherpetic neuralgia (PHN). The use of antivirals against VZV is essential in the treatment of HZ. However, limited antivirals are only licensed clinically for the treatment of HZ, including acyclovir, valacyclovir, famciclovir, brivudine, and amenamevir. Fortunately, some new antivirals against different types of
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.